沙美特罗氟替卡松对支气管哮喘患者肺功能的影响

Influence Analysis of Salmeterol Fluticasone and Budesonide to Lung Function of Patients with Bronchial Asthma

目的:探讨沙美特罗氟替卡松对持续支气管哮喘患者的治疗效果及肺功能的影响。方法:78例中度持续支气管哮喘患者随机分为A、B两组,A组给予沙美特罗氟替卡松治疗,B组作为对照组给予布地奈德治疗,观察两组治疗效果、1秒用力呼气容积(FEV1)、用力肺活量(FVC)、最高呼气流量(PEF)改善情况及不良反应发生率(鼻喉部、声嘶、局部刺激)。结果:A组治疗总有效率为92.31%,与B组79.49%比较,疗效明显提高,差异有统计学意义(P<0.05);两组患者治疗前FEVI、FVC、PEF指标无明显差异(P>0.05),治疗后较治疗前均有明显改善,但A组治疗后指标改善程度优于B组,差异存在统计学意义(P<0.05);A组不良反应发生率为5.13%,B组不良反应发生率为7.69%,两组无明显差异,差异无统计学意义(P>0.05)。结论:沙美特罗氟替卡松对持续支气管哮喘的疗效与肺功能改善效果较布地奈德更好,且并发症较少。

Objective： To probe into clinical effect of salmeterol fluticasone on patients of bronchial asthma cured and its effect on pulmonary function. Methods： Seventy-eight patients who suffered from the bronchial asthma and received treatment in our hospital from March,2012 to March,2014 were enrolled in this study. They were randomly divided into the group A and group B,with 39 patients in each group. The patients in group A were treated with the salmeterol fluticasone while in the B group treated with the budesonide. Then,the treatment effect,improvement of pulmonary function（ FEV1,FVC and PEF） and the occurrence rate of adverse reactions（ nasal and gular discomfort,trachyphonia and local excitation） of these two groups of patients were observed. Results： The whole effective rate of treatment in group A was 92. 31%,compared with 79. 49% in group B,and the differences were statistically significant（ P〈0. 05）. Before treatment,there were no differences in FEV1,FVC and PEF between group A and B. However,after treatment,the indexes were improved significantly and the indexes in group A were significantly better than their counterparts in B group（ P〈0. 05）. The occurrence rate of adverse reactions in group A was 5. 13%,compared with 7. 69% in group B,and the differences were not statistically significant（ P〉0. 05）. Conclusion： Salmeterol fluticasone is better than budesonide in treating chronic moderate bronchial asthma and in improving pulmonary function. Besides,salmeterol fluticasone results in less adverse reactions than budesonide. Therefore,salmeterol fluticasone deserves being promoted in the clinical application.